News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
15,304 Results
Type
Article (1072)
Company Profile (2)
Press Release (14230)
Section
Business (4174)
Career Advice (2)
Deals (930)
Drug Delivery (1)
Drug Development (1912)
Employer Resources (1)
FDA (390)
Job Trends (234)
News (7400)
Policy (766)
Tag
2024 Biotech Beach Digital (1)
Academia (36)
Adcomms (2)
Alliances (1859)
ALS (2)
Alzheimer's disease (251)
Antibody-drug conjugate (ADC) (4)
Approvals (385)
Autoimmune disease (1)
Bankruptcy (2)
Best Places to Work (176)
Biosimilars (2)
Breast cancer (6)
Cancer (41)
Cardiovascular disease (2)
Career advice (1)
Cell therapy (7)
Clinical research (1449)
Collaboration (20)
Compensation (6)
COVID-19 (47)
C-suite (4)
Cystic fibrosis (1)
Data (24)
Depression (1)
Diabetes (1)
Diagnostics (141)
Drug discovery (4)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (3)
Earnings (971)
Editorial (2)
Employer resources (1)
Events (1415)
Executive appointments (10)
FDA (410)
Fibrodysplasia Ossificans Progressiva (1)
Funding (11)
Gene therapy (1)
GLP-1 (29)
Government (59)
Guidances (1)
Healthcare (333)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (3)
Infectious disease (47)
Inflammatory bowel disease (3)
Intellectual property (2)
Interviews (1)
IPO (249)
Job creations (61)
Job search strategy (1)
Layoffs (12)
Legal (184)
Liver cancer (5)
Lung cancer (5)
Lymphoma (3)
Management (1)
Manufacturing (8)
Medical device (180)
Medtech (180)
Mergers & acquisitions (693)
Metabolic disorders (5)
Multiple sclerosis (1)
Neurodegenerative disease (10)
Neuroscience (255)
NextGen: Class of 2025 (61)
Non-profit (16)
Northern California (15)
Now hiring (1)
Obesity (4)
Opinion (4)
Ovarian cancer (2)
Pain (2)
Parkinson's disease (1)
People (1078)
Pharmaceutical (2)
Phase I (412)
Phase II (589)
Phase III (608)
Pipeline (15)
Podcasts (5)
Policy (1)
Postmarket research (68)
Preclinical (133)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (6)
Rare diseases (11)
Real estate (160)
Regulatory (575)
Reports (2)
Research institute (33)
Schizophrenia (3)
Series A (4)
Service/supplier (1)
Sickle cell disease (1)
Southern California (5)
Special edition (1)
Startups (98)
Stomach cancer (1)
The Weekly (5)
United States (203)
Vaccines (7)
Weight loss (1)
Date
Today (1)
Last 7 days (18)
Last 30 days (52)
Last 365 days (631)
2025 (98)
2024 (616)
2023 (756)
2022 (2076)
2021 (1872)
2020 (1307)
2019 (986)
2018 (634)
2017 (772)
2016 (640)
2015 (851)
2014 (667)
2013 (575)
2012 (668)
2011 (591)
2010 (495)
Location
Africa (7)
Arizona (1)
Asia (1060)
Australia (177)
California (24)
Canada (21)
China (3)
Europe (5611)
Florida (7)
Idaho (1)
Illinois (7)
Japan (14)
Maryland (5)
Massachusetts (56)
Michigan (5)
New Jersey (25)
New York (12)
North Carolina (7)
Northern California (15)
Pennsylvania (45)
South America (21)
Southern California (5)
Texas (5)
Utah (5)
Washington D.C. (1)
Washington State (1)
Wisconsin (1)
15,304 Results for "eisai gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American headquarters in Nutley, New Jersey. A company spokesperson said the pharma remains fully committed to the U.S. market.
February 28, 2025
·
1 min read
·
Angela Gabriel
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.
March 3, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
Leqembi’s sales in the U.S. continue to underwhelm, overshadowed by its growth in international markets.
February 7, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.
December 19, 2024
·
1 min read
·
Kate Goodwin
Press Releases
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
February 14, 2025
·
5 min read
Approvals
Biogen, Eisai Win Nod for Monthly Leqembi Maintenance Amid Stagnant Sales
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for patients with Alzheimer’s, could help with Leqembi’s thus far disappointing uptake and sales.
January 27, 2025
·
2 min read
·
Tristan Manalac
Business
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
July 1, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers
February 25, 2025
·
3 min read
Policy
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing.
June 9, 2024
·
19 min read
Policy
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
The filing of a Biologics License Application for a subcutaneous version of Biogen and Eisai’s Leqembi (lecanemab) has been delayed due to procedural reasons, the companies announced Monday.
April 1, 2024
·
2 min read
·
Tristan Manalac
1 of 1,531
Next
